Altria Group (NYSE:MO | MO Price Prediction) at $73.13 looks like a name to hold rather than add to. The yield is too rich to abandon, but the entry point is too high to fund with fresh capital while the U.S. consumer wobbles.
Altria sells Marlboro, Black & Mild cigars, Copenhagen and Skoal smokeless tobacco, on! nicotine pouches, and the impaired NJOY e-vapor unit. Shares have climbed 33.68% over the past year and 28.94% year to date, brushing a 52-week high of $74.56 and pushing past Wall Street consensus.
A 33% Rally Into a Slowing Consumer
The personal savings rate fell to 3.7% in Q1 2026 from 5.2% a year earlier, and aggregate personal saving has contracted 35.1% since early 2024. Premium tobacco pricing power depends on a consumer with less cushion.
Why the Yield Bulls Keep Adding
Altria delivered 7.3% adjusted EPS growth in Q1 2026, smokeable margins expanded to 65.1%, and management reaffirmed full-year 2026 adjusted EPS of $5.56 to $5.72. The annualized dividend sits at $4.24 after the 60th increase in 56 years, good for a 5.81% yield.
Altria returned $8 billion to shareholders in 2025 and has $720 million left on the buyback through year-end. With a 0.501 beta and a forward P/E of 13, this is the kind of low-volatility income story dividend investors hoard. Reddit’s r/dividendinvesting community holds a steady bullish 71 sentiment score on the name.
The Volume Story That Won’t Quit
The core business is shrinking. Domestic cigarette industry volumes fell roughly 5% in Q1 2026 after a 10.0% drop for full-year 2025. Marlboro retail share slipped 1.4 points to 39.7%, and the on! pouch share collapsed 4.2 points to 13.4% as competitors captured growth in the one category that should be a tailwind.
Discount cigarettes captured 33.3% of industry share, up 2.4 points, evidence of trade-down. NJOY ACE is sidelined by an ITC exclusion order after $2.2 billion in e-vapor impairments. Stockholders’ equity is negative $3.2 billion, and a CEO transition looms.
Why Patience Beats Conviction Here
Pricing power and buybacks can carry adjusted EPS to the 2.5% to 5.5% growth band guidance, but a Q1 revenue beat propped up by 610 million contract-manufactured export sticks is not organic strength. Collect the dividend, watch H2 2026 volume trends, and reserve fresh capital for a deeper pullback.
What the Numbers Show
Altria trades at $73.13 against a Wall Street consensus target of $70.36, implying roughly 3.7% downside. The trailing P/E is 15 and the forward multiple is 13, both modest but stretched against single-digit EPS growth.
The YTD return of 28.94% dwarfs the S&P 500’s roughly 6% YTD gain. Of 14 analysts covering the stock:
- Buy: 5
- Hold: 7
- Sell: 1
- Strong Sell: 1
The Verdict on Altria at $73
At $73, Altria is a Hold. The dividend is intact and growing, the buyback is funded, and management has reaffirmed guidance. None of that justifies a fresh entry above analyst consensus while Marlboro and on! both cede share and the savings rate craters. Existing holders are paid 5.81% to wait.
Conditions that would flip this to a Buy: a pullback toward the $64.46 200-day moving average, stabilization in Marlboro retail share, and evidence that on! is reclaiming pouch category points. Conditions that would flip it to a Sell: a guidance cut, a dividend coverage scare, or a 2027 outlook that fails to clear mid-single-digit EPS growth.
Watch the Q2 earnings report for organic smokeable volume excluding the export contract boost, the on! share line, and incoming CEO commentary on capital allocation discipline given negative $3.2 billion in equity.
At $73, Altria pays you to wait, but it does not pay you enough to chase.
Top Gaining Stocks
Top Losing Stocks